Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1996 May-Jun;69(3):211–224.

Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.

K D Bardhan 1
PMCID: PMC2589016  PMID: 9165690

Abstract

Acid-peptic disease is widely considered conquered or controlled, future advances being refinements of existing treatments rather than radical new developments. Yet controversies remain and developments have yet to be made. DUODENAL ULCER: Daily maintenance treatment with the anti-secretory drugs, histamine H2 receptor antagonists and proton pump blockers, controls duodenal ulcer effectively, markedly reducing relapse rate at one year after treatment from about 75 percent to 15 to 20 percent (and to about 10 percent on proton pump blockers). In contrast, Helicobacter pylori eradication with a one to two week course of treatment yields prolonged remission or cure. The consequent reduction in drug costs in individual patients, however, has been exceeded by increasing community use on the more expensive proton pump blockers for the treatment of gastroesophageal reflux disease. The marked decline in elective surgery since the introduction of histamine H2 receptor antagonists is commonly attributed to the power of these drugs. The fall, however, had started much earlier, indicating that the decline is due to changing natural history. In contrast, complication rates remain unaltered. An increasing proportion of newly diagnosed duodenal ulcer patients are elderly, and more of them now present for the first time with complications (in this center, about 40 percent), which consequently cannot be forestalled. Thus, duodenal ulcer disease is likely to remain a problem and in many will be a serious illness. GASTROESOPHAGEAL REFLUX DISEASE: The proton pump blockers have revolutionized the treatment of gastroesophageal reflux disease. In clinical trials they have proven markedly superior to the histamine H2 receptor antagonists in healing (at eight weeks, 80 to 90 percent vs. 50 to 60 percent), symptom relief, prevention of relapse on maintenance therapy and cost-effectiveness. However, several issues remain. The prevalence of gastroesophageal reflux disease seems to be rising and is now probably the commonest acid-peptic disease encountered in the West. Most clinical trials comparing proton pump blockers vs. histamine H2 receptor antagonists have been done in patients with erosive esophagitis, whereas the majority (50 to 60 percent) of patients with gastroesophageal reflux disease have milder, generally non-erosive, disease. The therapeutic gain of proton pump blockers diminishes in mild disease so may not be worth the higher drug costs. This is an important area for investigation. The majority of patients with erosive esophagitis relapse when treatment is stopped (about 75 percent at one year). Relapse is markedly reduced (to 20 to 25 percent) by daily maintenance treatment with proton pump blockers. Mild disease relapses less often, so longterm therapy by intermittent treatment may prove acceptable and more cost-effective than maintenance treatment. This strategy remains unexplored in trials. The ideal profile of an anti-secretory drug for intermittent treatment would combine rapid onset of action (similar to histamine H2 receptor antagonists) with powerful effect (as with proton pump blockers). The new class of drug, the reversible proton pump blocker (e.g., BY841) approaches this requirement.

Full text

PDF
211

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong D., Arnold R., Classen M., Fischer M., Goebell H., Schepp W., Blum A. L. RUDER--a prospective, two-year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. RUDER Study Group. Dig Dis Sci. 1994 Jul;39(7):1425–1433. doi: 10.1007/BF02088044. [DOI] [PubMed] [Google Scholar]
  2. Bader J. P., Delchier J. C. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther. 1994;8 (Suppl 1):47–52. doi: 10.1111/j.1365-2036.1994.tb00247.x. [DOI] [PubMed] [Google Scholar]
  3. Bardhan K. D. Can the H2 receptor antagonists change the natural history of duodenal ulcer disease? Am J Gastroenterol. 1994 Jan;89(1):3–6. [PubMed] [Google Scholar]
  4. Bardhan K. D., Cust G., Hinchliffe R. F., Williamson F. M., Lyon C., Bose K. Changing pattern of admissions and operations for duodenal ulcer. Br J Surg. 1989 Mar;76(3):230–236. doi: 10.1002/bjs.1800760307. [DOI] [PubMed] [Google Scholar]
  5. Bardhan K. D. Six years of continuous cimetidine treatment in peptic ulcer disease: efficacy and safety. Anglo-Irish Cimetidine Long-Term Study Group. Aliment Pharmacol Ther. 1988 Oct;2(5):395–405. doi: 10.1111/j.1365-2036.1988.tb00713.x. [DOI] [PubMed] [Google Scholar]
  6. Bardhan K. D. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1995;9 (Suppl 1):15–25. doi: 10.1111/j.1365-2036.1995.tb00779.x. [DOI] [PubMed] [Google Scholar]
  7. Bate C. M., Booth S. N., Crowe J. P., Mountford R. A., Keeling P. W., Hepworth-Jones B., Taylor M. D., Richardson P. D. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut. 1995 Apr;36(4):492–498. doi: 10.1136/gut.36.4.492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bianchi Porro G., Corinaldesi R., Lazzaroni M., Barbara L., Capurso L., Paoluzi P., Mangiameli A., Sabbatini F., Franceschi M., Bolling E. Long term treatment with omeprazole 20 mg three days a week or 10 mg daily in the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther. 1994 Oct;8(5):541–548. doi: 10.1111/j.1365-2036.1994.tb00328.x. [DOI] [PubMed] [Google Scholar]
  9. Boyd E. J., Penston J. G., Johnston D. A., Wormsley K. G. Does maintenance therapy keep duodenal ulcers healed? Lancet. 1988 Jun 11;1(8598):1324–1327. doi: 10.1016/s0140-6736(88)92131-9. [DOI] [PubMed] [Google Scholar]
  10. Colin-Jones D. G. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1995;9 (Suppl 1):9–14. doi: 10.1111/j.1365-2036.1995.tb00778.x. [DOI] [PubMed] [Google Scholar]
  11. Dent J., Yeomans N. D., Mackinnon M., Reed W., Narielvala F. M., Hetzel D. J., Solcia E., Shearman D. J. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut. 1994 May;35(5):590–598. doi: 10.1136/gut.35.5.590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Digestive Disease Week and the 95th annual meeting of the American Gastroenterological Association. San Diego, California, May 14-17, 1995. Abstracts. Gastroenterology. 1995 Apr;108(4 Suppl):A1–1412. [PubMed] [Google Scholar]
  13. Forbes G. M., Glaser M. E., Cullen D. J., Warren J. R., Christiansen K. J., Marshall B. J., Collins B. J. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet. 1994 Jan 29;343(8892):258–260. doi: 10.1016/s0140-6736(94)91111-8. [DOI] [PubMed] [Google Scholar]
  14. Graham D. Y., Hepps K. S., Ramirez F. C., Lew G. M., Saeed Z. A. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol. 1993 Nov;28(11):939–942. doi: 10.3109/00365529309098288. [DOI] [PubMed] [Google Scholar]
  15. Hallerbäck B., Unge P., Carling L., Edwin B., Glise H., Havu N., Lyrenäs E., Lundberg K. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology. 1994 Nov;107(5):1305–1311. doi: 10.1016/0016-5085(94)90531-2. [DOI] [PubMed] [Google Scholar]
  16. Henriksson A. E., Edman A. C., Held M., Wadström T. Helicobacter pylori and acute bleeding peptic ulcer. Eur J Gastroenterol Hepatol. 1995 Aug;7(8):769–771. [PubMed] [Google Scholar]
  17. Kuipers E. J., Uyterlinde A. M., Peña A. S., Hazenberg H. J., Bloemena E., Lindeman J., Klinkenberg-Knol E. C., Meuwissen S. G. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995 Sep;90(9):1401–1406. [PubMed] [Google Scholar]
  18. Kuster E., Ros E., Toledo-Pimentel V., Pujol A., Bordas J. M., Grande L., Pera C. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut. 1994 Jan;35(1):8–14. doi: 10.1136/gut.35.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Labenz J., Börsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion. 1994;55(1):19–23. doi: 10.1159/000201117. [DOI] [PubMed] [Google Scholar]
  20. Laufer S., Tries S., Augustin J., Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforschung. 1994 May;44(5):629–636. [PubMed] [Google Scholar]
  21. McColl K. E. The role of Helicobacter pylori eradication in the management of acute bleeding peptic ulcer. Eur J Gastroenterol Hepatol. 1995 Aug;7(8):753–755. [PubMed] [Google Scholar]
  22. McDougle A. M., Lancaster-Smith M. J., Higson D. L. Ranitidine maintenance therapy in the prevention of duodenal ulceration; a comparison of 150 mg at night with 300 mg at night. Aliment Pharmacol Ther. 1995 Jun;9(3):287–291. doi: 10.1111/j.1365-2036.1995.tb00383.x. [DOI] [PubMed] [Google Scholar]
  28. Patel P., Mendall M. A., Khulusi S., Molineaux N., Levy J., Maxwell J. D., Northfield T. C. Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy. Lancet. 1994 Aug 20;344(8921):511–512. doi: 10.1016/s0140-6736(94)91899-6. [DOI] [PubMed] [Google Scholar]
  29. Penston J. G. Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia. Aliment Pharmacol Ther. 1994 Aug;8(4):369–389. doi: 10.1111/j.1365-2036.1994.tb00304.x. [DOI] [PubMed] [Google Scholar]
  30. Penston J. G., Wormsley K. G. Nine years of maintenance treatment with ranitidine for patients with duodenal ulcer disease. Aliment Pharmacol Ther. 1992 Oct;6(5):629–645. doi: 10.1111/j.1365-2036.1992.tb00577.x. [DOI] [PubMed] [Google Scholar]
  31. Penston J., Wormsley K. G. Efficacy and safety of long-term maintenance therapy of duodenal ulcers. Scand J Gastroenterol. 1989 Nov;24(9):1145–1152. doi: 10.3109/00365528909089269. [DOI] [PubMed] [Google Scholar]
  32. Pounder R. E., Festen H., Korman M. The long-term management of duodenal ulceration using an H2-antagonist: symptomatic self-care compared with maintenance treatment. Aliment Pharmacol Ther. 1992 Jun;6(3):315–325. doi: 10.1111/j.1365-2036.1992.tb00053.x. [DOI] [PubMed] [Google Scholar]
  33. Reilly T. G., Ayres R. C., Poxon V., Walt R. P. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther. 1995 Oct;9(5):483–490. doi: 10.1111/j.1365-2036.1995.tb00410.x. [DOI] [PubMed] [Google Scholar]
  34. Reinbach D. H., Cruickshank G., McColl K. E. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection. Gut. 1993 Oct;34(10):1344–1347. doi: 10.1136/gut.34.10.1344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rush D. R., Stelmach W. J., Young T. L., Kirchdoerfer L. J., Scott-Lennox J., Holverson H. E., Sabesin S. M., Nicholas T. A. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract. 1995 Aug;41(2):126–136. [PubMed] [Google Scholar]
  36. Simon B., Schütz E., Müller P., Dixon J. S. Short report: long-term management of peptic ulcer disease with ranitidine in Germany. Aliment Pharmacol Ther. 1994 Feb;8(1):135–137. doi: 10.1111/j.1365-2036.1994.tb00171.x. [DOI] [PubMed] [Google Scholar]
  37. Singh P., Colin-Jones D. G. Modern management of peptic ulceration. Br J Hosp Med. 1992 Jan 9;47(1):44–50. [PubMed] [Google Scholar]
  38. Smout A. J., Jonkman J. H., Peeters P. A., De Bruin H. Effect of an evening dose of regular and effervescent formulations of ranitidine or cimetidine on intragastric pH in healthy volunteers. Aliment Pharmacol Ther. 1995 Feb;9(1):51–56. doi: 10.1111/j.1365-2036.1995.tb00351.x. [DOI] [PubMed] [Google Scholar]
  39. Sobala G. M., Crabtree J. E., Pentith J. A., Rathbone B. J., Shallcross T. M., Wyatt J. I., Dixon M. F., Heatley R. V., Axon A. T. Screening dyspepsia by serology to Helicobacter pylori. Lancet. 1991 Jul 13;338(8759):94–96. doi: 10.1016/0140-6736(91)90085-4. [DOI] [PubMed] [Google Scholar]
  40. Sonnenberg A., Townsend W. F. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med. 1995 May 8;155(9):922–928. [PubMed] [Google Scholar]
  41. Stalnikowicz-Darvasi R. H2 antagonists in the treatment of reflux esophagitis: a critical analysis. Am J Gastroenterol. 1989 Mar;84(3):245–248. [PubMed] [Google Scholar]
  42. Susi D., Neri M., Ballone E., Mezzetti A., Cuccurullo F. Five-year maintenance treatment with ranitidine: effects on the natural history of duodenal ulcer disease. Am J Gastroenterol. 1994 Jan;89(1):26–32. [PubMed] [Google Scholar]
  43. Tytgat G. N. Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther. 1994 Aug;8(4):359–368. doi: 10.1111/j.1365-2036.1994.tb00303.x. [DOI] [PubMed] [Google Scholar]
  44. Vigneri S., Termini R., Leandro G., Badalamenti S., Pantalena M., Savarino V., Di Mario F., Battaglia G., Mela G. S., Pilotto A. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995 Oct 26;333(17):1106–1110. doi: 10.1056/NEJM199510263331703. [DOI] [PubMed] [Google Scholar]
  45. Walan A., Bianchi-Porro G., Hentschel E., Bardhan K. D., Delattre M. Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol. 1987 May;22(4):397–405. doi: 10.3109/00365528708991481. [DOI] [PubMed] [Google Scholar]
  46. Walan A., Eriksson S. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer. Scand J Gastroenterol Suppl. 1994;201:91–97. doi: 10.3109/00365529409105373. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES